nodes	percent_of_prediction	percent_of_DWPC	metapath
Pseudoephedrine—IL2—lung cancer	0.677	1	CbGaD
Pseudoephedrine—NFATC1—mammary gland—lung cancer	0.00773	0.162	CbGeAlD
Pseudoephedrine—IL2—respiratory system—lung cancer	0.00471	0.099	CbGeAlD
Pseudoephedrine—IL2—epithelium—lung cancer	0.00394	0.0827	CbGeAlD
Pseudoephedrine—NFATC1—bone marrow—lung cancer	0.00302	0.0634	CbGeAlD
Pseudoephedrine—IL2—bone marrow—lung cancer	0.00276	0.058	CbGeAlD
Pseudoephedrine—NFATC1—lung—lung cancer	0.00274	0.0575	CbGeAlD
Pseudoephedrine—IL2—lung—lung cancer	0.0025	0.0526	CbGeAlD
Pseudoephedrine—NFATC1—lymph node—lung cancer	0.00187	0.0393	CbGeAlD
Pseudoephedrine—TNF—lymph node—lung cancer	0.00179	0.0375	CbGeAlD
Pseudoephedrine—IL2—lymph node—lung cancer	0.00171	0.0359	CbGeAlD
Pseudoephedrine—SLC6A3—respiratory system—lung cancer	0.00125	0.0262	CbGeAlD
Pseudoephedrine—SLC6A4—respiratory system—lung cancer	0.00114	0.024	CbGeAlD
Pseudoephedrine—SLC6A2—respiratory system—lung cancer	0.001	0.0211	CbGeAlD
Pseudoephedrine—ADRB1—bronchus—lung cancer	0.000972	0.0204	CbGeAlD
Pseudoephedrine—MAOA—respiratory system—lung cancer	0.000926	0.0194	CbGeAlD
Pseudoephedrine—ADRB1—cardiac atrium—lung cancer	0.00082	0.0172	CbGeAlD
Pseudoephedrine—ADRA1A—epithelium—lung cancer	0.000781	0.0164	CbGeAlD
Pseudoephedrine—MAOA—bronchus—lung cancer	0.000762	0.016	CbGeAlD
Pseudoephedrine—MAOA—trachea—lung cancer	0.000684	0.0144	CbGeAlD
Pseudoephedrine—SLC6A3—lung—lung cancer	0.000661	0.0139	CbGeAlD
Pseudoephedrine—MAOA—cardiac atrium—lung cancer	0.000643	0.0135	CbGeAlD
Pseudoephedrine—ADRB1—lung—lung cancer	0.000627	0.0132	CbGeAlD
Pseudoephedrine—SLC6A4—lung—lung cancer	0.000606	0.0127	CbGeAlD
Pseudoephedrine—ADRA2A—bronchus—lung cancer	0.000584	0.0123	CbGeAlD
Pseudoephedrine—SLC6A2—lung—lung cancer	0.000533	0.0112	CbGeAlD
Pseudoephedrine—ADRA2A—trachea—lung cancer	0.000525	0.011	CbGeAlD
Pseudoephedrine—ADRA2A—cardiac atrium—lung cancer	0.000493	0.0104	CbGeAlD
Pseudoephedrine—MAOA—lung—lung cancer	0.000492	0.0103	CbGeAlD
Pseudoephedrine—ADRA2A—lung—lung cancer	0.000377	0.00792	CbGeAlD
Pseudoephedrine—SLC6A2—lymph node—lung cancer	0.000365	0.00766	CbGeAlD
Pseudoephedrine—Bradycardia—Irinotecan—lung cancer	0.000354	0.00405	CcSEcCtD
Pseudoephedrine—Delirium—Doxorubicin—lung cancer	0.000347	0.00397	CcSEcCtD
Pseudoephedrine—Nausea—Pemetrexed—lung cancer	0.000346	0.00396	CcSEcCtD
Pseudoephedrine—Nausea—Gefitinib—lung cancer	0.000344	0.00393	CcSEcCtD
Pseudoephedrine—Anorexia—Vinblastine—lung cancer	0.000343	0.00393	CcSEcCtD
Pseudoephedrine—Asthenia—Teniposide—lung cancer	0.000339	0.00387	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Topotecan—lung cancer	0.000338	0.00387	CcSEcCtD
Pseudoephedrine—MAOA—lymph node—lung cancer	0.000336	0.00706	CbGeAlD
Pseudoephedrine—Anorexia—Topotecan—lung cancer	0.000333	0.00381	CcSEcCtD
Pseudoephedrine—Dysuria—Paclitaxel—lung cancer	0.000331	0.00379	CcSEcCtD
Pseudoephedrine—Anorexia—Erlotinib—lung cancer	0.00033	0.00377	CcSEcCtD
Pseudoephedrine—Vertigo—Vinorelbine—lung cancer	0.000329	0.00377	CcSEcCtD
Pseudoephedrine—Palpitations—Vinorelbine—lung cancer	0.000324	0.00371	CcSEcCtD
Pseudoephedrine—Bradycardia—Cisplatin—lung cancer	0.000321	0.00367	CcSEcCtD
Pseudoephedrine—Hypertension—Vinorelbine—lung cancer	0.000317	0.00362	CcSEcCtD
Pseudoephedrine—Selegiline—CYP2A6—lung cancer	0.000316	0.228	CrCbGaD
Pseudoephedrine—Insomnia—Erlotinib—lung cancer	0.000313	0.00358	CcSEcCtD
Pseudoephedrine—Decreased appetite—Vinblastine—lung cancer	0.000313	0.00358	CcSEcCtD
Pseudoephedrine—Chest pain—Vinorelbine—lung cancer	0.000312	0.00357	CcSEcCtD
Pseudoephedrine—Dyspnoea—Topotecan—lung cancer	0.000312	0.00357	CcSEcCtD
Pseudoephedrine—Arrhythmia—Irinotecan—lung cancer	0.00031	0.00355	CcSEcCtD
Pseudoephedrine—Dyspnoea—Erlotinib—lung cancer	0.000309	0.00353	CcSEcCtD
Pseudoephedrine—Pain—Vinblastine—lung cancer	0.000308	0.00352	CcSEcCtD
Pseudoephedrine—Dyspepsia—Topotecan—lung cancer	0.000308	0.00352	CcSEcCtD
Pseudoephedrine—Dyspepsia—Erlotinib—lung cancer	0.000305	0.00348	CcSEcCtD
Pseudoephedrine—Decreased appetite—Topotecan—lung cancer	0.000304	0.00348	CcSEcCtD
Pseudoephedrine—Arrhythmia—Gemcitabine—lung cancer	0.000302	0.00346	CcSEcCtD
Pseudoephedrine—Decreased appetite—Erlotinib—lung cancer	0.000301	0.00344	CcSEcCtD
Pseudoephedrine—Vomiting—Teniposide—lung cancer	0.0003	0.00343	CcSEcCtD
Pseudoephedrine—Pain—Topotecan—lung cancer	0.000299	0.00342	CcSEcCtD
Pseudoephedrine—Rash—Teniposide—lung cancer	0.000298	0.0034	CcSEcCtD
Pseudoephedrine—Dermatitis—Teniposide—lung cancer	0.000297	0.0034	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Vinblastine—lung cancer	0.000297	0.00339	CcSEcCtD
Pseudoephedrine—Pain—Erlotinib—lung cancer	0.000296	0.00339	CcSEcCtD
Pseudoephedrine—Headache—Teniposide—lung cancer	0.000296	0.00338	CcSEcCtD
Pseudoephedrine—Angina pectoris—Docetaxel—lung cancer	0.000292	0.00334	CcSEcCtD
Pseudoephedrine—Tachycardia—Vinorelbine—lung cancer	0.000292	0.00334	CcSEcCtD
Pseudoephedrine—Muscle spasms—Irinotecan—lung cancer	0.000291	0.00333	CcSEcCtD
Pseudoephedrine—Bradycardia—Paclitaxel—lung cancer	0.000288	0.0033	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Topotecan—lung cancer	0.000288	0.0033	CcSEcCtD
Pseudoephedrine—Anorexia—Vinorelbine—lung cancer	0.000285	0.00326	CcSEcCtD
Pseudoephedrine—Arrhythmia—Cisplatin—lung cancer	0.000282	0.00322	CcSEcCtD
Pseudoephedrine—Nausea—Teniposide—lung cancer	0.00028	0.00321	CcSEcCtD
Pseudoephedrine—Body temperature increased—Topotecan—lung cancer	0.000277	0.00316	CcSEcCtD
Pseudoephedrine—Body temperature increased—Erlotinib—lung cancer	0.000274	0.00313	CcSEcCtD
Pseudoephedrine—Vertigo—Irinotecan—lung cancer	0.000272	0.00311	CcSEcCtD
Pseudoephedrine—Dyspnoea—Vinorelbine—lung cancer	0.000267	0.00305	CcSEcCtD
Pseudoephedrine—Muscle spasms—Cisplatin—lung cancer	0.000264	0.00302	CcSEcCtD
Pseudoephedrine—Amphetamine—CYP2A6—lung cancer	0.000263	0.19	CrCbGaD
Pseudoephedrine—Hypertension—Irinotecan—lung cancer	0.000261	0.00299	CcSEcCtD
Pseudoephedrine—Decreased appetite—Vinorelbine—lung cancer	0.00026	0.00298	CcSEcCtD
Pseudoephedrine—Asthenia—Vinblastine—lung cancer	0.000258	0.00296	CcSEcCtD
Pseudoephedrine—ADRA2A—lymph node—lung cancer	0.000258	0.00542	CbGeAlD
Pseudoephedrine—Tremor—Cisplatin—lung cancer	0.000257	0.00294	CcSEcCtD
Pseudoephedrine—Pain—Vinorelbine—lung cancer	0.000256	0.00293	CcSEcCtD
Pseudoephedrine—Hypertension—Gemcitabine—lung cancer	0.000254	0.00291	CcSEcCtD
Pseudoephedrine—Arrhythmia—Paclitaxel—lung cancer	0.000253	0.0029	CcSEcCtD
Pseudoephedrine—Asthenia—Topotecan—lung cancer	0.000251	0.00287	CcSEcCtD
Pseudoephedrine—Chest pain—Gemcitabine—lung cancer	0.000251	0.00287	CcSEcCtD
Pseudoephedrine—Confusional state—Irinotecan—lung cancer	0.000249	0.00285	CcSEcCtD
Pseudoephedrine—Asthenia—Erlotinib—lung cancer	0.000248	0.00284	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Vinorelbine—lung cancer	0.000247	0.00282	CcSEcCtD
Pseudoephedrine—Tension—Paclitaxel—lung cancer	0.000242	0.00277	CcSEcCtD
Pseudoephedrine—Muscle spasms—Etoposide—lung cancer	0.000242	0.00277	CcSEcCtD
Pseudoephedrine—Nervousness—Paclitaxel—lung cancer	0.00024	0.00274	CcSEcCtD
Pseudoephedrine—Irritability—Methotrexate—lung cancer	0.000239	0.00273	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Irinotecan—lung cancer	0.000239	0.00273	CcSEcCtD
Pseudoephedrine—Dizziness—Vinblastine—lung cancer	0.000238	0.00272	CcSEcCtD
Pseudoephedrine—Muscle spasms—Paclitaxel—lung cancer	0.000237	0.00271	CcSEcCtD
Pseudoephedrine—Body temperature increased—Vinorelbine—lung cancer	0.000237	0.00271	CcSEcCtD
Pseudoephedrine—Anorexia—Irinotecan—lung cancer	0.000235	0.00269	CcSEcCtD
Pseudoephedrine—Benzyl alcohol—CYP2E1—lung cancer	0.000234	0.169	CrCbGaD
Pseudoephedrine—Anxiety—Cisplatin—lung cancer	0.000233	0.00266	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Gemcitabine—lung cancer	0.000232	0.00266	CcSEcCtD
Pseudoephedrine—Dizziness—Topotecan—lung cancer	0.000231	0.00265	CcSEcCtD
Pseudoephedrine—Tremor—Paclitaxel—lung cancer	0.000231	0.00264	CcSEcCtD
Pseudoephedrine—Benzyl alcohol—CYP1A1—lung cancer	0.000231	0.167	CrCbGaD
Pseudoephedrine—Anorexia—Gemcitabine—lung cancer	0.000229	0.00262	CcSEcCtD
Pseudoephedrine—Vomiting—Vinblastine—lung cancer	0.000229	0.00262	CcSEcCtD
Pseudoephedrine—Dizziness—Erlotinib—lung cancer	0.000229	0.00262	CcSEcCtD
Pseudoephedrine—Agitation—Paclitaxel—lung cancer	0.000227	0.00259	CcSEcCtD
Pseudoephedrine—Vertigo—Etoposide—lung cancer	0.000226	0.00259	CcSEcCtD
Pseudoephedrine—Headache—Vinblastine—lung cancer	0.000226	0.00258	CcSEcCtD
Pseudoephedrine—Selegiline—CYP2E1—lung cancer	0.000225	0.162	CrCbGaD
Pseudoephedrine—Insomnia—Irinotecan—lung cancer	0.000223	0.00255	CcSEcCtD
Pseudoephedrine—Vomiting—Topotecan—lung cancer	0.000222	0.00254	CcSEcCtD
Pseudoephedrine—Vertigo—Paclitaxel—lung cancer	0.000222	0.00253	CcSEcCtD
Pseudoephedrine—Rash—Topotecan—lung cancer	0.000221	0.00252	CcSEcCtD
Pseudoephedrine—Dermatitis—Topotecan—lung cancer	0.00022	0.00252	CcSEcCtD
Pseudoephedrine—Vomiting—Erlotinib—lung cancer	0.00022	0.00252	CcSEcCtD
Pseudoephedrine—Dyspnoea—Irinotecan—lung cancer	0.00022	0.00252	CcSEcCtD
Pseudoephedrine—Headache—Topotecan—lung cancer	0.000219	0.00251	CcSEcCtD
Pseudoephedrine—Tachycardia—Cisplatin—lung cancer	0.000219	0.0025	CcSEcCtD
Pseudoephedrine—Rash—Erlotinib—lung cancer	0.000218	0.0025	CcSEcCtD
Pseudoephedrine—Dermatitis—Erlotinib—lung cancer	0.000218	0.00249	CcSEcCtD
Pseudoephedrine—Palpitations—Paclitaxel—lung cancer	0.000218	0.00249	CcSEcCtD
Pseudoephedrine—Insomnia—Gemcitabine—lung cancer	0.000217	0.00249	CcSEcCtD
Pseudoephedrine—Dyspepsia—Irinotecan—lung cancer	0.000217	0.00249	CcSEcCtD
Pseudoephedrine—Hypertension—Etoposide—lung cancer	0.000217	0.00248	CcSEcCtD
Pseudoephedrine—Headache—Erlotinib—lung cancer	0.000217	0.00248	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Cisplatin—lung cancer	0.000217	0.00248	CcSEcCtD
Pseudoephedrine—Asthenia—Vinorelbine—lung cancer	0.000215	0.00246	CcSEcCtD
Pseudoephedrine—Decreased appetite—Irinotecan—lung cancer	0.000215	0.00245	CcSEcCtD
Pseudoephedrine—Arrhythmia—Docetaxel—lung cancer	0.000215	0.00245	CcSEcCtD
Pseudoephedrine—Dyspnoea—Gemcitabine—lung cancer	0.000214	0.00245	CcSEcCtD
Pseudoephedrine—Chest pain—Etoposide—lung cancer	0.000214	0.00245	CcSEcCtD
Pseudoephedrine—Nausea—Vinblastine—lung cancer	0.000214	0.00245	CcSEcCtD
Pseudoephedrine—Anorexia—Cisplatin—lung cancer	0.000214	0.00244	CcSEcCtD
Pseudoephedrine—Hypertension—Paclitaxel—lung cancer	0.000213	0.00244	CcSEcCtD
Pseudoephedrine—Pain—Irinotecan—lung cancer	0.000211	0.00241	CcSEcCtD
Pseudoephedrine—Chest pain—Paclitaxel—lung cancer	0.00021	0.0024	CcSEcCtD
Pseudoephedrine—Anxiety—Paclitaxel—lung cancer	0.000209	0.00239	CcSEcCtD
Pseudoephedrine—Decreased appetite—Gemcitabine—lung cancer	0.000209	0.00239	CcSEcCtD
Pseudoephedrine—Nausea—Topotecan—lung cancer	0.000208	0.00238	CcSEcCtD
Pseudoephedrine—Confusional state—Etoposide—lung cancer	0.000207	0.00237	CcSEcCtD
Pseudoephedrine—Pain—Gemcitabine—lung cancer	0.000206	0.00235	CcSEcCtD
Pseudoephedrine—Nausea—Erlotinib—lung cancer	0.000206	0.00235	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Irinotecan—lung cancer	0.000203	0.00233	CcSEcCtD
Pseudoephedrine—Confusional state—Paclitaxel—lung cancer	0.000203	0.00232	CcSEcCtD
Pseudoephedrine—Dysuria—Methotrexate—lung cancer	0.000202	0.00231	CcSEcCtD
Pseudoephedrine—Muscle spasms—Docetaxel—lung cancer	0.000201	0.0023	CcSEcCtD
Pseudoephedrine—Tachycardia—Etoposide—lung cancer	0.0002	0.00229	CcSEcCtD
Pseudoephedrine—Dyspnoea—Cisplatin—lung cancer	0.0002	0.00229	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Etoposide—lung cancer	0.000198	0.00227	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Gemcitabine—lung cancer	0.000198	0.00227	CcSEcCtD
Pseudoephedrine—Dizziness—Vinorelbine—lung cancer	0.000198	0.00226	CcSEcCtD
Pseudoephedrine—Tachycardia—Paclitaxel—lung cancer	0.000196	0.00225	CcSEcCtD
Pseudoephedrine—Anorexia—Etoposide—lung cancer	0.000196	0.00224	CcSEcCtD
Pseudoephedrine—Body temperature increased—Irinotecan—lung cancer	0.000195	0.00223	CcSEcCtD
Pseudoephedrine—Decreased appetite—Cisplatin—lung cancer	0.000195	0.00223	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Paclitaxel—lung cancer	0.000195	0.00223	CcSEcCtD
Pseudoephedrine—Anorexia—Paclitaxel—lung cancer	0.000192	0.00219	CcSEcCtD
Pseudoephedrine—Pain—Cisplatin—lung cancer	0.000192	0.00219	CcSEcCtD
Pseudoephedrine—Vomiting—Vinorelbine—lung cancer	0.00019	0.00218	CcSEcCtD
Pseudoephedrine—Body temperature increased—Gemcitabine—lung cancer	0.00019	0.00217	CcSEcCtD
Pseudoephedrine—Rash—Vinorelbine—lung cancer	0.000189	0.00216	CcSEcCtD
Pseudoephedrine—Dermatitis—Vinorelbine—lung cancer	0.000189	0.00216	CcSEcCtD
Pseudoephedrine—Headache—Vinorelbine—lung cancer	0.000187	0.00214	CcSEcCtD
Pseudoephedrine—Sweating—Methotrexate—lung cancer	0.000185	0.00211	CcSEcCtD
Pseudoephedrine—Palpitations—Docetaxel—lung cancer	0.000185	0.00211	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Cisplatin—lung cancer	0.000185	0.00211	CcSEcCtD
Pseudoephedrine—Dyspnoea—Etoposide—lung cancer	0.000183	0.00209	CcSEcCtD
Pseudoephedrine—Angina pectoris—Doxorubicin—lung cancer	0.000182	0.00209	CcSEcCtD
Pseudoephedrine—Insomnia—Paclitaxel—lung cancer	0.000182	0.00208	CcSEcCtD
Pseudoephedrine—Hypertension—Docetaxel—lung cancer	0.000181	0.00206	CcSEcCtD
Pseudoephedrine—Dyspnoea—Paclitaxel—lung cancer	0.000179	0.00205	CcSEcCtD
Pseudoephedrine—Decreased appetite—Etoposide—lung cancer	0.000178	0.00204	CcSEcCtD
Pseudoephedrine—Chest pain—Docetaxel—lung cancer	0.000178	0.00204	CcSEcCtD
Pseudoephedrine—Nausea—Vinorelbine—lung cancer	0.000178	0.00203	CcSEcCtD
Pseudoephedrine—Dyspepsia—Paclitaxel—lung cancer	0.000177	0.00203	CcSEcCtD
Pseudoephedrine—Body temperature increased—Cisplatin—lung cancer	0.000177	0.00203	CcSEcCtD
Pseudoephedrine—Asthenia—Irinotecan—lung cancer	0.000177	0.00203	CcSEcCtD
Pseudoephedrine—Pain—Etoposide—lung cancer	0.000176	0.00201	CcSEcCtD
Pseudoephedrine—Dysuria—Doxorubicin—lung cancer	0.000175	0.002	CcSEcCtD
Pseudoephedrine—Decreased appetite—Paclitaxel—lung cancer	0.000175	0.002	CcSEcCtD
Pseudoephedrine—Asthenia—Gemcitabine—lung cancer	0.000173	0.00197	CcSEcCtD
Pseudoephedrine—Pain—Paclitaxel—lung cancer	0.000172	0.00197	CcSEcCtD
Pseudoephedrine—Confusional state—Docetaxel—lung cancer	0.000172	0.00197	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Etoposide—lung cancer	0.000169	0.00194	CcSEcCtD
Pseudoephedrine—Tachycardia—Docetaxel—lung cancer	0.000167	0.0019	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Paclitaxel—lung cancer	0.000166	0.0019	CcSEcCtD
Pseudoephedrine—Dizziness—Irinotecan—lung cancer	0.000163	0.00187	CcSEcCtD
Pseudoephedrine—Anorexia—Docetaxel—lung cancer	0.000163	0.00186	CcSEcCtD
Pseudoephedrine—Body temperature increased—Etoposide—lung cancer	0.000162	0.00186	CcSEcCtD
Pseudoephedrine—Asthenia—Cisplatin—lung cancer	0.000161	0.00184	CcSEcCtD
Pseudoephedrine—Sweating—Doxorubicin—lung cancer	0.00016	0.00183	CcSEcCtD
Pseudoephedrine—Body temperature increased—Paclitaxel—lung cancer	0.000159	0.00182	CcSEcCtD
Pseudoephedrine—Vomiting—Irinotecan—lung cancer	0.000157	0.00179	CcSEcCtD
Pseudoephedrine—Rash—Irinotecan—lung cancer	0.000156	0.00178	CcSEcCtD
Pseudoephedrine—Dermatitis—Irinotecan—lung cancer	0.000155	0.00178	CcSEcCtD
Pseudoephedrine—Headache—Irinotecan—lung cancer	0.000155	0.00177	CcSEcCtD
Pseudoephedrine—Insomnia—Docetaxel—lung cancer	0.000154	0.00177	CcSEcCtD
Pseudoephedrine—Vomiting—Gemcitabine—lung cancer	0.000153	0.00175	CcSEcCtD
Pseudoephedrine—Bradycardia—Doxorubicin—lung cancer	0.000153	0.00175	CcSEcCtD
Pseudoephedrine—Dyspnoea—Docetaxel—lung cancer	0.000152	0.00174	CcSEcCtD
Pseudoephedrine—Rash—Gemcitabine—lung cancer	0.000152	0.00173	CcSEcCtD
Pseudoephedrine—Dermatitis—Gemcitabine—lung cancer	0.000151	0.00173	CcSEcCtD
Pseudoephedrine—Headache—Gemcitabine—lung cancer	0.000151	0.00172	CcSEcCtD
Pseudoephedrine—Dyspepsia—Docetaxel—lung cancer	0.00015	0.00172	CcSEcCtD
Pseudoephedrine—Decreased appetite—Docetaxel—lung cancer	0.000148	0.0017	CcSEcCtD
Pseudoephedrine—Asthenia—Etoposide—lung cancer	0.000147	0.00168	CcSEcCtD
Pseudoephedrine—Nausea—Irinotecan—lung cancer	0.000147	0.00168	CcSEcCtD
Pseudoephedrine—Pain—Docetaxel—lung cancer	0.000146	0.00167	CcSEcCtD
Pseudoephedrine—Asthenia—Paclitaxel—lung cancer	0.000144	0.00165	CcSEcCtD
Pseudoephedrine—Nausea—Gemcitabine—lung cancer	0.000143	0.00163	CcSEcCtD
Pseudoephedrine—Vomiting—Cisplatin—lung cancer	0.000142	0.00163	CcSEcCtD
Pseudoephedrine—Rash—Cisplatin—lung cancer	0.000141	0.00162	CcSEcCtD
Pseudoephedrine—Dermatitis—Cisplatin—lung cancer	0.000141	0.00161	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Docetaxel—lung cancer	0.000141	0.00161	CcSEcCtD
Pseudoephedrine—Dizziness—Etoposide—lung cancer	0.000136	0.00155	CcSEcCtD
Pseudoephedrine—Vertigo—Methotrexate—lung cancer	0.000135	0.00155	CcSEcCtD
Pseudoephedrine—Body temperature increased—Docetaxel—lung cancer	0.000135	0.00154	CcSEcCtD
Pseudoephedrine—Arrhythmia—Doxorubicin—lung cancer	0.000134	0.00153	CcSEcCtD
Pseudoephedrine—Dizziness—Paclitaxel—lung cancer	0.000133	0.00152	CcSEcCtD
Pseudoephedrine—Nausea—Cisplatin—lung cancer	0.000133	0.00152	CcSEcCtD
Pseudoephedrine—Vomiting—Etoposide—lung cancer	0.000131	0.00149	CcSEcCtD
Pseudoephedrine—Rash—Etoposide—lung cancer	0.000129	0.00148	CcSEcCtD
Pseudoephedrine—Dermatitis—Etoposide—lung cancer	0.000129	0.00148	CcSEcCtD
Pseudoephedrine—Headache—Etoposide—lung cancer	0.000129	0.00147	CcSEcCtD
Pseudoephedrine—Chest pain—Methotrexate—lung cancer	0.000128	0.00147	CcSEcCtD
Pseudoephedrine—Tension—Doxorubicin—lung cancer	0.000128	0.00146	CcSEcCtD
Pseudoephedrine—Vomiting—Paclitaxel—lung cancer	0.000128	0.00146	CcSEcCtD
Pseudoephedrine—Rash—Paclitaxel—lung cancer	0.000127	0.00145	CcSEcCtD
Pseudoephedrine—Dermatitis—Paclitaxel—lung cancer	0.000127	0.00145	CcSEcCtD
Pseudoephedrine—Nervousness—Doxorubicin—lung cancer	0.000127	0.00145	CcSEcCtD
Pseudoephedrine—Headache—Paclitaxel—lung cancer	0.000126	0.00144	CcSEcCtD
Pseudoephedrine—Muscle spasms—Doxorubicin—lung cancer	0.000125	0.00143	CcSEcCtD
Pseudoephedrine—Confusional state—Methotrexate—lung cancer	0.000124	0.00142	CcSEcCtD
Pseudoephedrine—Asthenia—Docetaxel—lung cancer	0.000122	0.0014	CcSEcCtD
Pseudoephedrine—Nausea—Etoposide—lung cancer	0.000122	0.00139	CcSEcCtD
Pseudoephedrine—Agitation—Doxorubicin—lung cancer	0.00012	0.00137	CcSEcCtD
Pseudoephedrine—Nausea—Paclitaxel—lung cancer	0.00012	0.00137	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Methotrexate—lung cancer	0.000119	0.00136	CcSEcCtD
Pseudoephedrine—Selegiline—ABCB1—lung cancer	0.000118	0.0849	CrCbGaD
Pseudoephedrine—Vertigo—Doxorubicin—lung cancer	0.000117	0.00134	CcSEcCtD
Pseudoephedrine—Anorexia—Methotrexate—lung cancer	0.000117	0.00134	CcSEcCtD
Pseudoephedrine—Palpitations—Doxorubicin—lung cancer	0.000115	0.00132	CcSEcCtD
Pseudoephedrine—Dizziness—Docetaxel—lung cancer	0.000113	0.00129	CcSEcCtD
Pseudoephedrine—Hypertension—Doxorubicin—lung cancer	0.000113	0.00129	CcSEcCtD
Pseudoephedrine—Insomnia—Methotrexate—lung cancer	0.000111	0.00127	CcSEcCtD
Pseudoephedrine—Chest pain—Doxorubicin—lung cancer	0.000111	0.00127	CcSEcCtD
Pseudoephedrine—Anxiety—Doxorubicin—lung cancer	0.000111	0.00127	CcSEcCtD
Pseudoephedrine—Dyspnoea—Methotrexate—lung cancer	0.00011	0.00125	CcSEcCtD
Pseudoephedrine—Vomiting—Docetaxel—lung cancer	0.000108	0.00124	CcSEcCtD
Pseudoephedrine—Dyspepsia—Methotrexate—lung cancer	0.000108	0.00124	CcSEcCtD
Pseudoephedrine—Rash—Docetaxel—lung cancer	0.000108	0.00123	CcSEcCtD
Pseudoephedrine—Dermatitis—Docetaxel—lung cancer	0.000107	0.00123	CcSEcCtD
Pseudoephedrine—Confusional state—Doxorubicin—lung cancer	0.000107	0.00123	CcSEcCtD
Pseudoephedrine—Decreased appetite—Methotrexate—lung cancer	0.000107	0.00122	CcSEcCtD
Pseudoephedrine—Headache—Docetaxel—lung cancer	0.000107	0.00122	CcSEcCtD
Pseudoephedrine—Pain—Methotrexate—lung cancer	0.000105	0.0012	CcSEcCtD
Pseudoephedrine—Tachycardia—Doxorubicin—lung cancer	0.000104	0.00119	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Doxorubicin—lung cancer	0.000103	0.00118	CcSEcCtD
Pseudoephedrine—Anorexia—Doxorubicin—lung cancer	0.000102	0.00116	CcSEcCtD
Pseudoephedrine—Nausea—Docetaxel—lung cancer	0.000101	0.00116	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Methotrexate—lung cancer	0.000101	0.00116	CcSEcCtD
Pseudoephedrine—Body temperature increased—Methotrexate—lung cancer	9.72e-05	0.00111	CcSEcCtD
Pseudoephedrine—Insomnia—Doxorubicin—lung cancer	9.63e-05	0.0011	CcSEcCtD
Pseudoephedrine—Dyspnoea—Doxorubicin—lung cancer	9.49e-05	0.00109	CcSEcCtD
Pseudoephedrine—Dyspepsia—Doxorubicin—lung cancer	9.37e-05	0.00107	CcSEcCtD
Pseudoephedrine—Decreased appetite—Doxorubicin—lung cancer	9.26e-05	0.00106	CcSEcCtD
Pseudoephedrine—Pain—Doxorubicin—lung cancer	9.11e-05	0.00104	CcSEcCtD
Pseudoephedrine—Asthenia—Methotrexate—lung cancer	8.82e-05	0.00101	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Doxorubicin—lung cancer	8.78e-05	0.001	CcSEcCtD
Pseudoephedrine—Body temperature increased—Doxorubicin—lung cancer	8.42e-05	0.000963	CcSEcCtD
Pseudoephedrine—Dizziness—Methotrexate—lung cancer	8.13e-05	0.00093	CcSEcCtD
Pseudoephedrine—Vomiting—Methotrexate—lung cancer	7.82e-05	0.000894	CcSEcCtD
Pseudoephedrine—Rash—Methotrexate—lung cancer	7.75e-05	0.000887	CcSEcCtD
Pseudoephedrine—Dermatitis—Methotrexate—lung cancer	7.75e-05	0.000886	CcSEcCtD
Pseudoephedrine—Headache—Methotrexate—lung cancer	7.7e-05	0.000881	CcSEcCtD
Pseudoephedrine—Asthenia—Doxorubicin—lung cancer	7.64e-05	0.000874	CcSEcCtD
Pseudoephedrine—Nausea—Methotrexate—lung cancer	7.3e-05	0.000835	CcSEcCtD
Pseudoephedrine—Dizziness—Doxorubicin—lung cancer	7.04e-05	0.000805	CcSEcCtD
Pseudoephedrine—Vomiting—Doxorubicin—lung cancer	6.77e-05	0.000774	CcSEcCtD
Pseudoephedrine—Rash—Doxorubicin—lung cancer	6.71e-05	0.000768	CcSEcCtD
Pseudoephedrine—Dermatitis—Doxorubicin—lung cancer	6.71e-05	0.000767	CcSEcCtD
Pseudoephedrine—Headache—Doxorubicin—lung cancer	6.67e-05	0.000763	CcSEcCtD
Pseudoephedrine—Nausea—Doxorubicin—lung cancer	6.33e-05	0.000723	CcSEcCtD
Pseudoephedrine—MAOA—Metabolism—PIK3CB—lung cancer	4.75e-06	2.55e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—NQO1—lung cancer	4.75e-06	2.54e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—PTGS2—lung cancer	4.71e-06	2.52e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—HES1—lung cancer	4.69e-06	2.51e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—CXCL8—lung cancer	4.65e-06	2.49e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—TP53—lung cancer	4.62e-06	2.47e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—ERBB3—lung cancer	4.62e-06	2.47e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PIK3CG—lung cancer	4.61e-06	2.47e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—APC—lung cancer	4.61e-06	2.47e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—KIT—lung cancer	4.61e-06	2.47e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—NRAS—lung cancer	4.61e-06	2.47e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—RAF1—lung cancer	4.6e-06	2.47e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—EGF—lung cancer	4.56e-06	2.44e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—IL2—lung cancer	4.55e-06	2.43e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—APOA1—lung cancer	4.54e-06	2.43e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—APC—lung cancer	4.51e-06	2.41e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PIK3CG—lung cancer	4.51e-06	2.41e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—KIT—lung cancer	4.51e-06	2.41e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—NRAS—lung cancer	4.51e-06	2.41e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—PIK3CB—lung cancer	4.5e-06	2.41e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—EGF—lung cancer	4.46e-06	2.39e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—IL2—lung cancer	4.44e-06	2.38e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—TERT—lung cancer	4.43e-06	2.37e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—HRAS—lung cancer	4.42e-06	2.37e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—MAPK3—lung cancer	4.41e-06	2.36e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—POMC—lung cancer	4.39e-06	2.35e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—BRAF—lung cancer	4.33e-06	2.32e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—CXCL8—lung cancer	4.32e-06	2.31e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—MAPK3—lung cancer	4.32e-06	2.31e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—FGFR1—lung cancer	4.3e-06	2.3e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—POMC—lung cancer	4.29e-06	2.3e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—ERBB3—lung cancer	4.29e-06	2.3e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—IL6R—lung cancer	4.28e-06	2.29e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—STK11—lung cancer	4.28e-06	2.29e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CREBBP—lung cancer	4.27e-06	2.29e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—BRAF—lung cancer	4.24e-06	2.27e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—HIF1A—lung cancer	4.23e-06	2.27e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—EGFR—lung cancer	4.2e-06	2.25e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—IL6R—lung cancer	4.19e-06	2.24e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CREBBP—lung cancer	4.18e-06	2.24e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PIK3CG—lung cancer	4.14e-06	2.22e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—IL2—lung cancer	4.13e-06	2.21e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—TERT—lung cancer	4.11e-06	2.2e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—EGFR—lung cancer	4.11e-06	2.2e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—PTEN—lung cancer	4.11e-06	2.2e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—APOA1—lung cancer	4.09e-06	2.19e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MAP2K1—lung cancer	4.08e-06	2.18e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PIK3CD—lung cancer	4.05e-06	2.17e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—KDR—lung cancer	4.05e-06	2.17e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR downstream signaling—PIK3CA—lung cancer	4.01e-06	2.15e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—FGFR1—lung cancer	3.99e-06	2.14e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MAP2K1—lung cancer	3.99e-06	2.14e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—KRAS—lung cancer	3.97e-06	2.12e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PIK3CD—lung cancer	3.96e-06	2.12e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—GSTP1—lung cancer	3.96e-06	2.12e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—POMC—lung cancer	3.95e-06	2.11e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—HIF1A—lung cancer	3.93e-06	2.11e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR downstream signaling—PIK3CA—lung cancer	3.93e-06	2.1e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—EP300—lung cancer	3.92e-06	2.1e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—AKT1—lung cancer	3.9e-06	2.09e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—KRAS—lung cancer	3.88e-06	2.08e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—CAT—lung cancer	3.85e-06	2.06e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—CREBBP—lung cancer	3.84e-06	2.06e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—APOA1—lung cancer	3.8e-06	2.03e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—KDR—lung cancer	3.76e-06	2.01e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—ABCB1—lung cancer	3.75e-06	2.01e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—KIT—lung cancer	3.73e-06	2e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—APC—lung cancer	3.73e-06	2e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PIK3CG—lung cancer	3.73e-06	2e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—NRAS—lung cancer	3.73e-06	2e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—EGF—lung cancer	3.69e-06	1.97e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—TYMS—lung cancer	3.68e-06	1.97e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—PIK3CA—lung cancer	3.65e-06	1.95e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PIK3CD—lung cancer	3.64e-06	1.95e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—GSTM1—lung cancer	3.64e-06	1.95e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MDM2—lung cancer	3.63e-06	1.94e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—RAF1—lung cancer	3.62e-06	1.94e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—ALB—lung cancer	3.6e-06	1.93e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—ERBB2—lung cancer	3.58e-06	1.92e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—MAPK3—lung cancer	3.57e-06	1.91e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—PIK3CA—lung cancer	3.57e-06	1.91e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MDM2—lung cancer	3.55e-06	1.9e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—POMC—lung cancer	3.55e-06	1.9e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—RAF1—lung cancer	3.54e-06	1.9e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MTOR—lung cancer	3.53e-06	1.89e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PIK3CB—lung cancer	3.53e-06	1.89e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—BRAF—lung cancer	3.51e-06	1.88e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—ERBB2—lung cancer	3.5e-06	1.87e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—KIT—lung cancer	3.47e-06	1.86e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PIK3CG—lung cancer	3.47e-06	1.86e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—APC—lung cancer	3.47e-06	1.86e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—NRAS—lung cancer	3.47e-06	1.86e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—IL6R—lung cancer	3.46e-06	1.85e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CREBBP—lung cancer	3.46e-06	1.85e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MTOR—lung cancer	3.46e-06	1.85e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PIK3CB—lung cancer	3.46e-06	1.85e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—CYP1A1—lung cancer	3.45e-06	1.85e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—EGF—lung cancer	3.43e-06	1.83e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—ERCC2—lung cancer	3.42e-06	1.83e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—EGFR—lung cancer	3.4e-06	1.82e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CXCL8—lung cancer	3.39e-06	1.82e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—HRAS—lung cancer	3.37e-06	1.81e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CXCL8—lung cancer	3.32e-06	1.78e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—MAPK3—lung cancer	3.32e-06	1.78e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MAP2K1—lung cancer	3.3e-06	1.77e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—HRAS—lung cancer	3.3e-06	1.77e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—POMC—lung cancer	3.3e-06	1.77e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR downstream signaling—AKT1—lung cancer	3.28e-06	1.76e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PIK3CD—lung cancer	3.28e-06	1.76e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—BRAF—lung cancer	3.26e-06	1.74e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CASP3—lung cancer	3.25e-06	1.74e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—PIK3CA—lung cancer	3.25e-06	1.74e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—IL2—lung cancer	3.24e-06	1.74e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—IL6—lung cancer	3.23e-06	1.73e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—IL6R—lung cancer	3.22e-06	1.72e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CREBBP—lung cancer	3.21e-06	1.72e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—KRAS—lung cancer	3.21e-06	1.72e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR downstream signaling—AKT1—lung cancer	3.21e-06	1.72e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CASP3—lung cancer	3.18e-06	1.7e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PIK3CB—lung cancer	3.18e-06	1.7e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—IL2—lung cancer	3.17e-06	1.7e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CCND1—lung cancer	3.16e-06	1.69e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—IL6—lung cancer	3.16e-06	1.69e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—EGFR—lung cancer	3.16e-06	1.69e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—JUN—lung cancer	3.16e-06	1.69e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PTGS2—lung cancer	3.15e-06	1.68e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CCND1—lung cancer	3.09e-06	1.66e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—JUN—lung cancer	3.09e-06	1.65e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MMP9—lung cancer	3.07e-06	1.64e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MAP2K1—lung cancer	3.07e-06	1.64e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CDKN1A—lung cancer	3.06e-06	1.64e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PTEN—lung cancer	3.05e-06	1.63e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PIK3CD—lung cancer	3.05e-06	1.63e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—PIK3CA—lung cancer	3.02e-06	1.62e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MMP9—lung cancer	3e-06	1.61e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CDKN1A—lung cancer	2.99e-06	1.6e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PTEN—lung cancer	2.99e-06	1.6e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—KRAS—lung cancer	2.98e-06	1.6e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—AKT1—lung cancer	2.98e-06	1.59e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—APOA1—lung cancer	2.96e-06	1.58e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—PIK3CA—lung cancer	2.95e-06	1.58e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MDM2—lung cancer	2.94e-06	1.57e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—RAF1—lung cancer	2.93e-06	1.57e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—AKT1—lung cancer	2.91e-06	1.56e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—EP300—lung cancer	2.91e-06	1.56e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—PIK3CA—lung cancer	2.9e-06	1.55e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—ERBB2—lung cancer	2.9e-06	1.55e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PIK3CB—lung cancer	2.86e-06	1.53e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MTOR—lung cancer	2.86e-06	1.53e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—EP300—lung cancer	2.85e-06	1.52e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—SRC—lung cancer	2.83e-06	1.52e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—SRC—lung cancer	2.77e-06	1.48e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—VEGFA—lung cancer	2.76e-06	1.48e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CXCL8—lung cancer	2.75e-06	1.47e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PTEN—lung cancer	2.74e-06	1.47e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—PIK3CA—lung cancer	2.74e-06	1.47e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—STAT3—lung cancer	2.73e-06	1.46e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MDM2—lung cancer	2.73e-06	1.46e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—HRAS—lung cancer	2.73e-06	1.46e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—NRAS—lung cancer	2.72e-06	1.46e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—RAF1—lung cancer	2.72e-06	1.46e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PIK3CG—lung cancer	2.7e-06	1.45e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—VEGFA—lung cancer	2.7e-06	1.44e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—ERBB2—lung cancer	2.69e-06	1.44e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—STAT3—lung cancer	2.67e-06	1.43e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—NRAS—lung cancer	2.66e-06	1.43e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PIK3CB—lung cancer	2.66e-06	1.42e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MTOR—lung cancer	2.66e-06	1.42e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—AKT1—lung cancer	2.65e-06	1.42e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CASP3—lung cancer	2.63e-06	1.41e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—IL2—lung cancer	2.62e-06	1.41e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—EP300—lung cancer	2.62e-06	1.4e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—IL6—lung cancer	2.61e-06	1.4e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MAPK3—lung cancer	2.61e-06	1.4e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—POMC—lung cancer	2.57e-06	1.38e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CCND1—lung cancer	2.56e-06	1.37e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—JUN—lung cancer	2.55e-06	1.37e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CXCL8—lung cancer	2.55e-06	1.37e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MAPK3—lung cancer	2.55e-06	1.37e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MYC—lung cancer	2.54e-06	1.36e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—HRAS—lung cancer	2.54e-06	1.36e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—CREBBP—lung cancer	2.5e-06	1.34e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MMP9—lung cancer	2.48e-06	1.33e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MYC—lung cancer	2.48e-06	1.33e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—EGFR—lung cancer	2.48e-06	1.33e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CDKN1A—lung cancer	2.48e-06	1.33e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PTEN—lung cancer	2.47e-06	1.32e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	2.47e-06	1.32e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CASP3—lung cancer	2.44e-06	1.31e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—IL2—lung cancer	2.44e-06	1.31e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—EGFR—lung cancer	2.43e-06	1.3e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—IL6—lung cancer	2.43e-06	1.3e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—AKT1—lung cancer	2.41e-06	1.29e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CCND1—lung cancer	2.38e-06	1.27e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PIK3CD—lung cancer	2.37e-06	1.27e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—JUN—lung cancer	2.37e-06	1.27e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—AKT1—lung cancer	2.37e-06	1.27e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—EP300—lung cancer	2.36e-06	1.26e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—KRAS—lung cancer	2.34e-06	1.25e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—ALB—lung cancer	2.34e-06	1.25e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MMP9—lung cancer	2.31e-06	1.24e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	2.3e-06	1.23e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PTEN—lung cancer	2.29e-06	1.23e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—KRAS—lung cancer	2.29e-06	1.23e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—SRC—lung cancer	2.29e-06	1.23e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—AKT1—lung cancer	2.24e-06	1.2e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—VEGFA—lung cancer	2.23e-06	1.19e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—STAT3—lung cancer	2.21e-06	1.18e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—NRAS—lung cancer	2.2e-06	1.18e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—EP300—lung cancer	2.19e-06	1.17e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PIK3CA—lung cancer	2.15e-06	1.15e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—SRC—lung cancer	2.13e-06	1.14e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MAPK3—lung cancer	2.11e-06	1.13e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PIK3CA—lung cancer	2.11e-06	1.13e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—TP53—lung cancer	2.08e-06	1.12e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—VEGFA—lung cancer	2.07e-06	1.11e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PIK3CB—lung cancer	2.07e-06	1.11e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MYC—lung cancer	2.05e-06	1.1e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—STAT3—lung cancer	2.05e-06	1.1e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PTGS2—lung cancer	2.05e-06	1.1e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—NRAS—lung cancer	2.05e-06	1.1e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—TP53—lung cancer	2.04e-06	1.09e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—EGFR—lung cancer	2.01e-06	1.07e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—HRAS—lung cancer	1.99e-06	1.07e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MAPK3—lung cancer	1.96e-06	1.05e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—HRAS—lung cancer	1.95e-06	1.04e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PIK3CA—lung cancer	1.94e-06	1.04e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MYC—lung cancer	1.91e-06	1.02e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—IL6—lung cancer	1.91e-06	1.02e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—KRAS—lung cancer	1.9e-06	1.02e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—IL6—lung cancer	1.87e-06	9.99e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—EGFR—lung cancer	1.87e-06	9.99e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PTEN—lung cancer	1.79e-06	9.58e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—KRAS—lung cancer	1.76e-06	9.43e-06	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—AKT1—lung cancer	1.76e-06	9.42e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PIK3CA—lung cancer	1.74e-06	9.33e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—AKT1—lung cancer	1.72e-06	9.21e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—EP300—lung cancer	1.71e-06	9.13e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—TP53—lung cancer	1.69e-06	9.02e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	1.62e-06	8.67e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—HRAS—lung cancer	1.61e-06	8.63e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—AKT1—lung cancer	1.58e-06	8.47e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—TP53—lung cancer	1.57e-06	8.39e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—IL6—lung cancer	1.54e-06	8.26e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—HRAS—lung cancer	1.5e-06	8.02e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—IL6—lung cancer	1.43e-06	7.68e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—AKT1—lung cancer	1.42e-06	7.62e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—AKT1—lung cancer	1.32e-06	7.08e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PIK3CA—lung cancer	1.26e-06	6.75e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—AKT1—lung cancer	1.03e-06	5.52e-06	CbGpPWpGaD
